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Objective: This work aimed to compare the evolution of visual outcomes in Leber
hereditary optic neuropathy (LHON) patients treated with intravitreal gene therapy to the
spontaneous evolution in prior natural history (NH) studies.
Design: A combined analysis of two phase three randomized, double-masked,
sham-controlled studies (REVERSE and RESCUE) and their joint long-term extension
trial (CLIN06) evaluated the efficacy of rAAV2/2-ND4 vs. 11 pooled NH studies used as
an external control.
Subjects: The LHON subjects carried the m.11778G>A ND4 mutation and were aged
≥15 years at onset of vision loss.
Methods: A total of 76 subjects received a single intravitreal rAAV2/2-ND4 injection in
one eye and sham injection in the fellow eye within 1 year after vision loss in REVERSE
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and RESCUE. Both eyes were considered as treated due to the rAAV2/2-ND4 treatment
efficacy observed in the contralateral eyes. Best corrected visual acuity (BCVA) from
REVERSE, RESCUE, and CLIN06 up to 4.3 years after vision loss was compared to
the visual acuity of 208 NH subjects matched for age and ND4 genotype. The NH
subjects were from a LHON registry (REALITY) and from 10 NH studies. A locally
estimated scatterplot smoothing (LOESS), non-parametric, local regression model was
used to modelize visual acuity curves over time, and linear mixed model was used for
statistical inferences.
Main Outcome Measures: The main outcome measure was evolution of visual acuity
from 12months after vision loss, when REVERSE and RESCUE patients had been treated
with rAAV2/2-ND4.
Results: The LOESS curves showed that the BCVA of the treated patients progressively
improved from month 12 to 52 after vision loss. At month 48, there was a statistically
and clinically relevant difference in visual acuity of−0.33 logarithm of the minimal angle of
resolution (LogMAR) (16.5 ETDRS letters equivalent) in favor of treated eyes vs. NH eyes
(p< 0.01). Most treated eyes (88.7%) were on-chart at month 48 as compared to 48.1%
of the NH eyes (p < 0.01). The treatment effect at last observation remained statistically
and clinically significant when adjusted for age and duration of follow-up (−0.32 LogMAR,
p < 0.0001).
Conclusions: The m.11778G>A LHON patients treated with rAAV2/2-ND4 exhibited
an improvement of visual acuity over more than 4 years after vision loss to a degree not
demonstrated in NH studies.
Clinical Trial Registration: NCT02652767, NCT02652780, NCT03406104,
and NCT03295071.
Keywords: Leber hereditary optic neuropathy, ND4, gene therapy, natural history, visual acuity
INTRODUCTION
Leber hereditary optic neuropathy (LHON) is a rare genetic
disease caused by mutations of mitochondrial genes of the
respiratory chain complex I, leading to selective degeneration of
retinal ganglion cells and optic nerve atrophy (1). The disease
typically manifests as severe central visual loss in one eye,
followed by second eye involvement with a median interval
of 8 weeks (2–4). The decline in visual acuity is subacute to
rapidly progressive, with visual acuity usually deteriorating to
values worse than 20/200 over a few months after onset (2, 5).
Such sudden and profound vision loss occurring in well-sighted
individuals, usually young adults, has a dramatic impact on
their quality of life (5). Thus, targeted drug discovery and
new therapeutic approaches are crucial to improve the visual
prognosis of patients with LHON.While the oral drug idebenone
has shown some benefit (6–8), leading to its approval for the
treatment of LHON in Europe, there is still a pressing medical
need for further therapies with a significant therapeutic benefit in
LHON (7).
Among the three most common point mutations found in
LHON, the m.11778G>A mutation in the mitochondrial ND4
gene is the most prevalent, accounting for ∼70% of LHON
patients worldwide (9). Moreover, it is associated with a poor
prognosis, with spontaneous visual recovery limited to <15% of
patients, as shown by a recent meta-analysis of 695 patients with
the m.11778G>A mutation (10).
rAAV2/2-ND4 (also called lenadogene nolparvovec) is
a replication-defective, recombinant adeno-associated virus
vector serotype 2 (rAAV2) containing a codon-modified
complementary DNA (cDNA) encoding the human wild-
type mitochondrial ND4 protein. It is believed to restore the
functional ND4 protein, thereby preventing the neuronal
degeneration of retinal ganglion cells, as demonstrated in a rat
model of LHON (11). In a phase 1/2 study conducted in 15
LHON patients harboring the m.11778G>A ND4 mutation
(hereafter named MT-ND4 patients), a single intravitreal
injection (IVT) of lenadogene nolparvovec was well-tolerated
and associated with a clinically significant improvement in
visual function outcomes (12, 13). A visual benefit induced
by lenadogene nolparvovec was recently suggested by two
randomized, double-masked, sham-controlled phase three
studies REVERSE [patients with a vision loss between 6 and
12 months; NCT02652780 (14)] and RESCUE [patients with
a vision loss below 6 months; NCT02652767 (15)]. In both
studies, lenadogene nolparvovec was injected in one eye, while
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the fellow eye received a sham injection, with the unexpected
result of sustained visual improvement in both eyes. At 96 weeks
post-injection, the mean gain from nadir (worst vision point)
in REVERSE and RESCUE studies was, respectively, +28 and
+26 in treated eyes and +24 and +23 ETDRS letters in sham
eyes (14, 15). The REVERSE and RESCUE patients are currently
followed in an extension study for up to 5 years after injection
(CLIN06, NCT03406104). This bilateral improvement after
the unilateral injection of a gene therapy product has also
been observed in other clinical studies of LHON (16, 17). A
mechanistic explanation could be transfer of the viral vector
from the injected eye to the contralateral eye through the optic
chiasm, as suggested by a non-human primate biodistribution
study using unilaterally injected lenadogene nolparvovec (14).
In order to better characterize the efficacy of gene therapy in
MT-ND4 LHON patients, we indirectly compared the evolution
of visual outcomes of treated patients in the REVERSE, RESCUE,
and CLIN06 studies to the spontaneous evolution of natural
history patients from a LHON registry study and previously
published reports of LHON patients with visual outcome data
used as an external control.
METHODS
Patients Treated With Gene
Therapy—Efficacy Pool
We analyzed the evolution of best corrected visual acuity
(BCVA) from a pooled dataset of 76 LHON patients treated
with a single IVT injection of lenadogene nolparvovec. The
BCVA data were collected from study inclusion to week 96
after treatment in REVERSE (NCT02652780) (14) and RESCUE
(NCT02652767) (15) and from week 96 after treatment to the
last available observation in the ongoing long-term follow-up
CLIN06 study of REVERSE and RESCUE (NCT03406104) (see
Supplementary Table 1).
The study design and results of REVERSE and RESCUE
have been previously reported (14, 15). Briefly, REVERSE and
RESCUE were randomized, double-masked, sham-controlled,
multi-center phase 3 clinical trials with a similar design, aiming
at evaluating the efficacy and safety of lenadogene nolparvovec
in LHON patients. The right eye of each subject was randomly
allocated to receive either lenadogene nolparvovec or sham
treatment in a 1:1 allocation ratio. The fellow (left) eye received
the treatment not allocated to the right eye. Lenadogene
nolparvovec at 9× 1010 viral genomes (vg)/eye was administered
once via a single IVT. Sham IVT injection was performed once
by applying pressure to the eye at the location of a typical
procedure using the blunt end of a syringe without a needle. Both
studies enrolled symptomatic LHON patients aged 15 years or
older and harboring the m.11778G>A ND4 mutation. The only
difference between the two studies was the timing of the onset
of vision loss: from 181 to 365 days in both eyes in REVERSE
and ≤180 days in the first-affected eye in RESCUE. A total of
37 patients (REVERSE) and 39 patients (RESCUE) were enrolled
and treated.
All REVERSE and RESCUE patients who completed the study
up to week 96 after injection were offered to participate in the
extension CLIN06 study, for a total of 5 years of follow-up after
injection. A total of 62 patients (31 from REVERSE and 31 from
RESCUE) were enrolled in the extension study which is ongoing.
For our analysis, we used all available BCVA data at the time of
this report, including assessments up to 4 years after injection.
Based on clinical results and non-human primate data (14), both
treated and sham eyes were considered exposed to the study drug
and pooled in the treated patient group.
The protocols of all three studies (RESCUE, REVERSE, and
CLIN06) were approved by local independent ethics committees,
and informed consent was obtained from all participants. All
studies were performed in compliance with Good Clinical
Practice and adhered to the ethical principles outlined in the
Declaration of Helsinki.
Natural History Patients—External Control
Group—Natural History Pool
Natural history patients (those not treated with lenadogene
nolparvovec, although they could have been treated with
idebenone), with age and LHON genotype adjusted to those
of treated patients, were used as an external control for the
analysis. To this end, we created a large database containing
visual outcome data from 11 studies originating from two main
sources: (i) the REALITY LHON registry (NCT03295071) (18)
sponsored by GenSight Biologics and (ii) 10 published studies on
LHON identified after a systematic review of the literature (3, 19–
27). Studies were included in the database only if they reported
individual (patient- and eye-level) visual acuity values along with
documentation of the time after vision loss in cohorts of at
least fiveMT-ND4 patients. For relevant comparison with treated
patients, we included only patients from the pooled database
who matched the inclusion criteria of REVERSE and RESCUE
as regards age and LHON genotype (i.e., symptomatic LHON
patients carrying the m.11778G>A ND4 mutation who were 15
years or older at the onset of vision loss). Further details on
REALITY and on the systematic literature review are provided
in the Supplementary Methods and Supplementary Table 1.
Handling of Data
For the analyses, all visual acuity values (from treated and natural
history patients) were converted to logarithm of the minimal
angle of resolution (LogMAR) using standard formula for on-
chart eyes (28) and the following conventions for off-chart
eyes: patients only able to count fingers or detect hand motion
were assigned LogMAR values of +2.0 and +2.3, respectively,
according to the Lange scale (29); light perception and no
light perception visual acuities were assigned LogMAR values
of +4.0 and +4.5, respectively, to align with the equivalence
used in the lenadogene nolparvovec studies and the REALITY
registry (14, 15, 18). All eyes were assigned a LogMAR value
of 0 at 1 month before the onset of vision loss, in line with
the normal visual acuity of LHON mutation carriers before
expression of the disease as described in the literature (30, 31)
and pre-symptomatic data of lenadogene nolparvovec studies
and REALITY registry. All extracted data and conversions of
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TABLE 1 | Description of the population.
Treated (N = 76) Natural history (N = 208) Total (N = 284) P-value
Number of eyes with visual acuity values 152 408a 560
Gender
Male (%) 61 (80.3%) 142 (82.6%) 203 (81.9%) 0.67 (C)
Missing data 0 36b 36
Age at onset of vision loss (years)
Median 32.5 23.5 25.0 <0.01 (KW)
Range 15.0–69.0 15.0–71.0 15.0–71.0
Number of visual acuity assessments per patient
Median 26.0 2.0 2.0 <0.01 (KW)
Mean (SD) 26.8 (5.2) 4.1 (4.0) 10.2 (11.0)
Patient follow-up since vision loss (months)c
Median 39.8 25.3 34.6 0.01 (KW)
Range 8.1–51.5 0.0–768.0 0.0–768.0
Q1–Q3 32.1–44.1 4.0–108.4 7.6–49.5
Patients with follow-up >36 months 64.5% 38.0% 45.1% <0.01 (C)
Time from vision loss to treatment (months)
Median 6.5 NA NA NA
Range 2.3–12.8 NA NA
C, chi-square test; KW, Kruskal–Wallis test; NA, not applicable; SD, standard deviation.
aEight natural history patient had visual acuity values in one eye only, leading to a sample size of 408 eyes.
bAll gender missing data were from the natural history study of Lam in 2014 (20).
cDefined as the time from vision loss to the last available visual acuity value, regardless of the eye.
visual acuity values to LogMAR underwent a thorough quality
control process for ensuring the accuracy of all LogMAR
reported values.
Statistical Methods
All data from treated and natural history patients were imported
in a pooled database for the analyses. All analyses were performed
at the patient level and at the eye level.
In a first step, we explored graphically the evolution of visual
acuity in treated and natural history eyes more than 12 months
after vision loss, when all REVERSE and RESCUE patients
would have been treated with rAAV2/2-ND4, using a locally
estimated scatterplot smoothing (LOESS), non-parametric, local
regression model in which each patient’s eyes were considered
independently. Smoothing parameters were based on the
corrected Akaike Information Criterion (SAS default method
with values from 0.3 to 0.6). LOESS curves with 95% confidence
interval (CI) were presented from 12 months up to 52 months
after vision loss, corresponding to the maximal duration of
follow-up for treated eyes in the extension study. All subsequent
visual acuity values of natural history eyes were assigned to
the 52-month timepoint using the next observation carried
backward method. Using this method, all visual acuity values
from the efficacy and natural history pools could be plotted on
the same figure.
In a second step, we compared the visual outcomes between
treated eyes and natural history eyes at 12, 18, 24, 36, and
48 months after vision loss (when all treated eyes were on
treatment) and at the last available visual acuity value. For
the 12- to 48-month analysis, only the closest value to the
nominal timepoint was selected for each eye based on pre-
specified time windows (month 12: [9;15] months; Month 18:
[15;21] months; Month 24: [21;30] months; Month 36: [30;42]
months; Month 48: [42;54] months). Conversely, for the analysis
at the last available visual acuity value, final visual acuity values
from all eyes were considered in the analysis, maximizing the
sample size. The following visual outcomes were analyzed: visual
acuity values in LogMAR, eye response rates at a threshold
of LogMAR ≤ 1.6 (on-chart values on the ETDRS scale) and
LogMAR ≤ 1.3 (cutoff for blindness according to WHO), and
eye response rates with an improvement from nadir ≥ 0.3. For
improvement from nadir, only eyes with at least two visual
acuity assessments were selected for the analyses. Comparisons
of visual outcomes were performed by a non-parametric test
(Kruskal–Wallis for visual acuity values and chi-square test
for eye response rates). In addition, a parametric model with
repeated measures on patients was also used for the analyses on
both eyes in order to take into account the inter-eye correlation
of each patient (mixed-model analysis of covariance for visual
acuity values and generalized linear mixed model for eye
response rate).
In order to control the potential confounding covariates in
the comparative analysis, the treatment effect at last available
visual acuity value was also estimated by a multivariate analysis
with repeated measures on patients. Age at onset of vision loss,
gender, and duration of follow-up were explored as covariates in
the multivariate analysis.
Additional analyses were also performed separately
considering only the better eye and worse eye of each patient.
Better eye and worse eye were selected based on their visual
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acuity value at last available evaluation or at their nadir in cases
of identical values at last available evaluation or on their mean
value in cases of identical nadir values. For patients who had
visual acuity data in one eye only, the eye was included in both
better-eye and worse-eye analyses.
All statistical analyses were carried out with SAS R© software
version 9.4. Statistical significance was set at P < 0.05.
RESULTS
Characteristics of the Analyzed Population
Among the 44 patients enrolled in the REALITY study, 23
were MT-ND4 LHON aged 15 years or older. Among the 304
MT-ND4 patients in the natural history studies, 185 met the
inclusion criteria of age at onset ≥ 15 years and at least one
available visual acuity value with time from onset of vision
loss. Thus, a total of 208 eligible natural history patients (408
eyes) were used as the external control cohort for comparison
with the 76 treated patients (152 eyes) from the REVERSE
and RESCUE studies (see Supplementary Table 1 and Table 1
for details).
The characteristics of the patients at onset of vision loss are
described in Table 1. Overall, both treated and natural history
patients were typical of the MT-ND4 LHON population with a
high proportion of males (81.9%) and a young age at onset of
vision loss (median, 25 years). Natural history patients had a
younger age of onset (median, 23.5 years) compared to treated
patients (median, 32.5 years).
The mean number of visual acuity assessments per patient
was larger in the treated group (26.8) as compared with the
natural history group (4.1). Treated patients had a longer
median follow-up duration after vision loss (39.8 months) than
natural history patients (25.3 months). Conversely, the follow-
up values of treated patients were distributed over a narrow
range (25% of patients have been followed for more than
44.1 months; maximal follow-up, 51.5 months) as opposed to a
wider distribution for natural history patients (25% of patients
were followed for more than 108.4 months; maximal follow-up,
768 months).
The treated patients received lenadogene nolparvovec
injection between 2.3 and 12.8 months after vision loss (median,
6.5 months). Half of the eyes (54%) had received treatment at
month 6 ([3, 9] months) after vision loss, nearly all eyes (93%)
at month 12 ([9, 15] months) after vision loss, and all patients
(100%) at month 18 ([15, 21] months) after vision loss. We
started the indirect comparison at month 12, which coincided
with the time when nearly all eyes had received treatment.
Global Evolution of Visual Acuity Over Time
The LOESS regression curve for treated patients (in red
in Figure 1; see Supplementary Figure 1 for the scatterplot)
showed a progressive and sustained improvement of BCVA from
month 12 up to month 52. Notably, the lowest point of the curve
(corresponding to the worst visual acuities) remained on-chart,
with BCVA values not exceeding 1.6 LogMAR.
The natural history patients showed a clear distinctive pattern
from treated patients as illustrated by the LOESS regression
FIGURE 1 | Evolution of visual acuities of treated eyes vs. natural history
eyes. The evolution of visual acuities over time for treated eyes (n = 152) and
natural history eyes (n = 408) was estimated by LOESS regression (solid line)
with 95% confidence interval around the fitted curve (shaded area). Smoothing
parameter: 0.332 for treated eyes and 0.408 for natural history eyes. *A
statistically significant difference between treated and natural history eyes is
illustrated by the non-overlapping confidence intervals (CI) of LOESS curves.
#Mean differences and 95% CI at month 48 were computed based on a
separate analysis described in Table 2.
curves shown in blue in Figure 1 (see Supplementary Figure 1
for the scatterplot). In natural history patients, visual acuities
plateaued around 1.6 LogMAR, with no recovery over 2 years
(up to month 36 after vision loss). A progressive and continuous
decline to off-chart values was then noted from month 36 up
to month 52. The 52-month timepoint shown in Figure 1 also
takes into account all subsequent visual acuity values of natural
history patients.
The divergence observed between the two curves from
month 12 after vision loss is further evidenced by the absence
of overlap in 95% CI at all later timepoints. Indeed the natural
history patients showed an absence of visual recovery over the
entire period from month 12 to 52, whereas the treated patients
showed a gradual and consistent improvement over the same
time period.
The treatment effect was also observed when REVERSE
and RESCUE studies were analyzed separately, showing a
similar improvement in the visual acuity LOESS curve of
the treated patients vs. the external control group (see
Supplementary Figures 2, 3).
Additionally, the treatment effect for both eyes was also
observed when the better eye and worse eye of patients were
analyzed separately.
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TABLE 2 | Visual acuity of treated eyes vs. natural history eyes with time intervals
from vision loss.
Time from vision loss Treated
(N = 152 eyes)
Natural history
(N = 408 eyes)
Month 12—[9, 15] months
Number of eyes 150 76
Visual acuity (LogMAR)
Median 1.55 1.70
Mean (SD) 1.57 (0.55) 1.69 (0.67)
95% CI (mean) (1.48, 1.66) (1.54, 1.84)
Mean difference (95% CI) 0.118# (−0.047, 0.282)
Month 18—[15, 21] months
Number of eyes 149 57
Visual acuity (LogMAR)
Median 1.40 1.60
Mean (SD) 1.46 (0.51) 1.60 (0.54)
95% CI (mean) (1.38, 1.54) (1.46, 1.75)
Mean difference (95% CI) 0.144# (−0.017, 0.304)
Month 24—[21, 30] months
Number of eyes 146 80
Visual acuity (LogMAR)
Median 1.40 1.52
Mean (SD) 1.40 (0.59) 1.54 (0.52)
95% CI (mean) (1.30, 1.50) (1.42, 1.65)
Mean difference (95% CI) 0.139## (−0.016, 0.293)
Month 36—[30, 42] months
Number of eyes 128 66
Visual acuity (LogMAR)
Median 1.30 1.55
Mean (SD) 1.33 (0.59) 1.52 (0.47)
95% CI (mean) (1.23, 1.44) (1.40, 1.63)
Mean difference (95% CI) 0.183##, * (0.018, 0.348)
Month 48—[42, 54] months
Number of eyes 62 27
Visual acuity (LogMAR)
Median 1.30 1.62
Mean (SD) 1.26 (0.45) 1.59 (0.44)
95% CI (mean) (1.14, 1.37) (1.41, 1.76)
Mean difference (95% CI) 0.329##, ** (0.125, 0.534)
CI, confidence interval; LogMAR, logarithm of the minimal angle of resolution; SD,
standard deviation.
The time from vison loss was calculated for each eye of each patient. For each eye, only the
closest value to the nominal timepoint was selected based on the time windows indicated
in brackets.
#P < 0.05, ##P < 0.01: statistically significant differences vs. natural history eyes using
Kruskal–Wallis test.
*P < 0.05, **P < 0.01: statistically significant difference vs. natural history eyes using
mixed ANCOVA with repeated measures on a patient.
Comparison of Visual Acuities at Each
Timepoint
Table 2 presents the results from month 12 to 48 after vision
loss when treated eyes had been injected with lenadogene
nolparvovec. In agreement with LOESS regression curves,
quantitative analyses showed better visual acuity of treated
eyes when compared with natural history eyes at all evaluated
timepoints from month 12 to 48. The difference in mean visual
acuity between treated and natural history eyes was statistically
significant at all time points based on a non-parametric Kruskal–
Wallis test and at month 36 and 48 based on a mixed ANCOVA
model, taking into account the inter-eye correlation for each
patient. The mean visual acuities with 95% CI for treated
eyes and natural history eyes were, respectively, 1.26 (1.14,
1.37) and 1.59 (1.41, 1.76) LogMAR at month 48 (p < 0.01
for both Kruskal–Wallis and mixed ANCOVA), with a mean
difference of 0.33 (0.12, 0.53) LogMAR in favor of treated
eyes (Table 2). The median visual acuities for treated eyes and
natural history eyes were, respectively, 1.30 vs. 1.62 LogMAR
at month 48.
The treatment effect was also observed when REVERSE
and RESCUE studies were analyzed separately vs. the external
control group. The mean visual acuity difference with 95% CI
between treated eyes and natural history eyes at month 48 was
0.31 (0.10, 0.52) LogMAR for REVERSE (p < 0.01 for both
statistical tests) and 0.49 (0.08, 0.89) LogMAR for RESCUE
(p = 0.03 for both statistical tests) in favor of treated eyes (see
Supplementary Table 2).
Similar results were obtained when better eyes and worse eyes
were analyzed separately, although a statistical significance was
not reached at all timepoints (see Supplementary Table 3).
Comparison of Visual Acuities at Last
Available Observation
Table 3 presents the analyses at last available visual acuities
comparing treated eyes vs. natural history eyes, with separate
analyses performed for each study (REVERSE and RESCUE) and
for better and worse eyes.
The mean visual acuities with 95% CI for treated and natural
history eyes were, respectively, 1.36 (1.27, 1.46) and 1.68 (1.62,
1.74) LogMAR at the last observation (p< 0.01 for both Kruskal–
Wallis and mixed ANCOVA), with a mean difference of 0.31
(0.20, 0.43) LogMAR in favor of treated eyes. The median
visual acuities for treated eyes and natural history eyes were,
respectively, 1.40 and 1.70 LogMAR.
For REVERSE and RESCUE studies, the mean BCVAs with
95% CI for treated eyes were 1.29 (1.18, 1.40) and 1.43 (1.27,
1.59) LogMAR, respectively, while the mean visual acuity for
natural history eyes was 1.68 (1.62, 1.74) LogMAR. The mean
difference with 95% CI between REVERSE treated eyes and
natural history eyes was 0.38 (0.24, 0.53) LogMAR in favor
of treated eyes (p < 0.01 for both statistical tests). The mean
difference between RESCUE treated eyes and natural history eyes
was 0.25 (0.10, 0.40) LogMAR in favor of treated eyes (p < 0.01
for both statistical tests). The median visual acuity was 1.30 for
REVERSE and 1.40 for RESCUE, vs. a median LogMAR of 1.70
for natural history eyes.
For analyses performed on better eyes, the mean visual
acuities with 95% CI for treated and natural history eyes were,
respectively, 1.24 (1.12, 1.37) and 1.57 (1.49, 1.65) LogMAR at the
last observation (p < 0.01 for Kruskal–Wallis test), with a mean
difference of 0.32 (0.17, 0.48) LogMAR in favor of treated eyes.
For analyses performed on worse eyes, the mean visual acuities
with 95% CI for treated eyes and natural history eyes were,
respectively, 1.48 (1.33, 1.63) and 1.79 (1.71, 1.86) LogMAR at the
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last observation (p < 0.01 for Kruskal–Wallis test), with a mean
difference of 0.31 (0.15, 0.46) LogMAR in favor of treated eyes.
Multivariate Analysis of Visual Acuities
We performed a multivariate analysis to explore the potential
impact of age at onset, gender, and duration of follow-up on
the treatment effect at last visual acuity observation. Both age
at onset (p = 0.0050) and follow-up duration (p = 0.0108)
showed a statistically significant effect on visual acuity: younger
patients and those with a shorter follow-up had better visual
acuity independent of treatment. In contrast, gender had no effect
on visual acuity outcome (p= 0.9236).
When considering the significant covariates in the analysis
(age at onset and duration of follow-up), the treatment effect was
confirmed in favor of treated eyes, with a statistically significant
least squares mean difference in visual acuity of 0.32 (0.20, 0.44)
LogMAR as compared with natural history eyes (p < 0.0001)
(Table 4).
Eye Response Rates
At month 48 after vision loss, most (55/62) treated eyes [88.7%;
95% CI (78.1, 95.3)] were on-chart (LogMAR≤ 1.6) as compared
to less than half of the eyes (13/27) in the natural history group
[48.1%, 95% CI (28.7, 68.1)] (Figure 2, left panel). The difference
was statistically significant at p < 0.01 with both statistical tests
(with or without considering the inter-eye correlation of each
patient). Comparable results were observed for the response rates
using the 1.3-LogMAR threshold (cutoff for blindness according
to WHO criteria) (Figure 2, right panel). At month 48, 34/62
treated eyes [54.8%; 95% CI (41.7, 67.5%)] were responders as
compared to 8/27 [29.6%, 95% CI (13.8, 50.2)] in the natural
history group (p= 0.03 with chi-square test).
At last observation, 122/152 treated eyes [80.3%; 95% CI
(73.0, 86.3)] were on-chart (LogMAR ≤ 1.6), as compared to
181/408 natural history eyes [44.4%; 95% CI (39.5, 49.3%)],
with a statistically significant difference with both statistical tests
(p < 0.01) (Figure 2, left panel). Similar results were observed
when evaluating the REVERSE and RESCUE studies separately,
with 85.1% [95% CI (75.0, 92.3)] and 75.6% [95% CI (64.6, 84.7)]
of treated eyes being on-chart at last observation, respectively
(p < 0.01 with both statistical tests vs. natural history eyes).
When using the 1.3-LogMAR response threshold at last
observation, 71/152 treated eyes [46.7%; 95% CI (38.6, 55.0)]
were responders as compared to 111/408 natural history eyes
[27.2%; 95% CI (22.9, 31.8)] (p < 0.01 with both statistical tests)
(Figure 2, right panel).
The proportion of eyes showing a meaningful improvement
from nadir of at least 0.3 LogMAR was greater in the treated
group as compared to the natural history group: 35/62 [56.5%;
95% CI (43.3, 69.0)] of treated eyes vs. 4/25 [16.0%; 95% CI (4.5,
36.1)] of natural history eyes at month 48 [p < 0.01 (chi-square)
and p = 0.02 (repeated measures)] and 75/152 [49.3%, 95% CI
(41.1, 57.6)] of treated eyes vs. 36/127 [28.3%; 95%CI (20.7, 37.0)]
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TABLE 4 | Visual acuity in treated eyes vs. natural history eyes at last
observation—multivariate analysis with age and duration of follow-up as
covariates.
Treated
(N = 152 eyes)
Natural history
(N = 408 eyes)
Number of eyes 152 408
Time from vision loss to last
observation (months)
Median (range) 39.9 (8.1–51.5) 28.4 (0.0–768.0)
Visual acuity (LogMAR)
LS means (95% CI) 1.36 (1.26, 1.46) 1.68 (1.62, 1.74)
Effect estimate with 95% CI 0.32 (0.20, 0.44)***
CI, confidence interval; LogMAR, logarithm of the minimal angle of resolution; LS,
least squares.
***P < 0.0001: statistically significant treatment effect using multivariate analysis, with age
and duration of follow-up as covariates (repeated measures on a patient).
The treatment effect on responder rates observed for both
eyes was similar to that seen when considering better eyes or
worse eyes.
DISCUSSION
In this pooled analysis, we demonstrated a sustained and
clinically relevant improvement in the visual acuities of MT-
ND4 LHON patients treated with lenadogene nolparvovec when
compared to the spontaneous evolution of vision in an external
control group comprised of natural history genetically and age-
matched LHON patients.
The RESCUE and REVERSE studies demonstrated bilateral
visual improvement after unilateral injection with lenadogene
nolparvovec in MT-ND4 LHON patients (14, 15). As the visual
improvement was observed in both treated and sham eyes,
the primary endpoint, which was based on the difference from
baseline between sham and treated eyes, was not met in both
studies. RESCUE included subjects at an earlier stage of LHON
who had not yet reached their nadir at the time of treatment,
so it is perhaps not unexpected that visual outcomes at week 96
had not recovered to the baseline values along the early curve
of anticipated visual decline despite clear improvement from
nadir. Indeed, from a clinical standpoint, the level of visual
improvement achieved from nadir was substantial in both
studies, with a mean gain in ETDRS letters at week 96 after
treatment of +28 and +24 in REVERSE and of +26 and
+23 in RESCUE for treated eyes and sham eyes, respectively.
Surprisingly, the earlier treatment (within 6 months after vision
loss) in RESCUE did not provide better outcomes than in
REVERSE (between 6 and 12 months after vision loss). However,
these results are still striking considering that a clinically relevant
improvement of visual acuity remains an uncommon feature in
MT-ND4 LHON subjects.
In a recent meta-analysis of untreated MT-ND4 LHON
patients aged at least 15 years at onset of vision loss reported
in the world literature, only 11.3% of patients showed some
spontaneous visual recovery, although the definitions used for
recovery varied among studies (10). In contrast, the great
majority of treated patients (81% for REVERSE and 71% for
RESCUE) had a clinically relevant recovery in BCVA from nadir
at week 96 after treatment when using a valid recovery endpoint
endorsed by an international group of experts (7, 15). While
these results are strongly supportive of a treatment-related effect
in REVERSE and RESCUE, the absence of an adequate placebo
group of untreated subjects in both studies precludes drawing
definitive conclusions regarding treatment benefit.
Here we try to address this issue by comparing the visual
outcomes of treated patients to an external control group of
individual natural historyMT-ND4 LHONpatients. The use of an
external control in supporting treatment efficacy is acknowledged
by many regulatory agencies, and this approach has been
increasingly used in rare diseases and in oncology trials where
the use of a placebo group is not ethically feasible (32, 33). In
this regard, a number of groups, including ours, have conducted
LHON registry studies for use as external comparators in drug
trials (20, 26, 34). However, these registries are usually limited
in size owing to the rarity of the disease, thereby limiting the
statistical power of such comparisons. In our own LHON registry
study, REALITY, we included a total of 44 LHON patients,
of whom only 23 met the inclusion criteria of REVERSE and
RESCUE trials (18). In order to reach a sufficient sample size
to enable a statistically meaningful comparison with treated
patients, we complemented our natural history dataset with
patient-level data identified through a systematic review of the
literature. This allowed us to build a large database of 208 natural
history LHON patients who shared the same characteristics as
those included in REVERSE and RESCUE.
This work is the first to thoroughly describe the spontaneous
evolution of visual acuity after vision loss in such a large cohort
of natural history MT-ND4 LHON patients. We showed that,
in natural history eyes, after the initial acute phase of visual
acuity decline to nadir, visual acuity plateaued with no recovery
over 2 years (from month 12 to 36 after vision loss). These data
are consistent with the known temporal course of clinical and
pathophysiological changes in LHON described in the literature
(2, 5, 35). Interestingly, in our study, the stable phase of natural
history patients was followed by a trend for a later decline in
visual acuity from 3 years after onset, suggesting that visual
outcomes may continue to deteriorate.
The first thorough investigation of the natural history of visual
function of LHON patients dates back to 1963 when van Senus
provided a detailed individual description of a Dutch cohort
of 27 LHON pedigrees, of whom 12 were later molecularly
confirmed as carrying the MT-ND4 mutation (36, 37). While
we could not include these patients in our analyses due to the
imprecision of reported visual acuity values (available only as
ranges) and uncertainty regarding the timing of measurements
after vision loss, these natural history data are overall coherent
with those described in our analyses. Indeed the majority of
MT-ND4 patients aged 15 years or older from the van Senus
cohort had a poor visual acuity at the time of investigation,
with 110/121 (91%) eyes having visual acuity worse than 6/60
(20/200; LogMAR +1.0), 100/121 (83%) eyes worse than 3/60
(20/400; LogMAR+1.3), and 69/121 (57%) eyes worse than 6/300
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FIGURE 2 | Eye responder rates at month 48 since vision loss and at last observation. LogMAR, logarithm of the minimal angle of resolution; n, number of eyes.
Response rates (%) are defined as the proportion of eyes with visual acuity values ≤ 1.6 LogMAR (left panel) or ≤ 1.3 LogMAR (right panel). Error bars represent 95%
confidence interval. #P < 0.05, ##P < 0.01: statistically significant difference vs. natural history eyes using chi-square test. **P < 0.01: statistically significant
difference vs. natural history eyes using a generalized linear mixed model with repeated measures on a patient.
(20/1,000; LogMAR +1.7). Among those MT-ND4 patients for
whom two visual acuity points in time were reported, only 5/54
(9%) eyes in four patients had documented improvement in
visual acuity of at least −0.2 LogMAR between onset of vision
loss and time of investigation (36).
In our analysis, a young age at onset was an independent
predictor of better visual outcomes. A better prognosis is known
to be driven by onset in children of 12 years old or younger (10,
38–40). Here we report that better visual outcomes at younger
ages may hold true for patients aged 15 years or older at onset.
In contrast to the evolution seen in natural history eyes,
treated eyes followed a clearly distinct pattern, with a sustained,
continuous, and progressive improvement in visual acuity from
12 to 52 months after the onset of vision loss. At month 48, there
was a statistically significant and clinically relevant difference in
the mean visual acuity of 0.33 LogMAR (+16.5 ETDRS letters
equivalent) in favor of treated eyes as compared to natural
history eyes (p < 0.01). This level of improvement translated
into a better quality of life for patients in both the REVERSE
and RESCUE studies, especially for mental health, dependency,
and role difficulty dimensions as measured by the National
Eye Institute Visual Function Questionnaire-25 (14, 15). It is
noteworthy that the improvement exceeded +15 ETDRS letters,
a response level recognized as clinically relevant by regulators
(41). Moreover, the magnitude of the treatment effect was
not impacted when known confounding variables (onset age
and duration of follow-up) were accounted for in multivariate
analyses, with a statistically significant and clinically relevant
mean difference of 0.32 LogMAR (+16 ETDRS letters) at the
last visual acuity measurement in favor of treated eyes. As
regards responder rates, most treated eyes (89%) were on-chart at
month 48, compared to less than half (48%) of the natural history
eyes (cutoff for response: LogMAR ≤ 1.6). When using the 1.3-
LogMAR cutoff for blindness, the responder rates at month 48
(LogMAR ≤ 1.3) were 55% for treated eyes vs. 30% for natural
history eyes. Similarly, a higher proportion of treated eyes had
a gain from nadir of at least 0.3 LogMAR when compared with
natural history eyes (57 vs. 16% at month 48). However, the
nadir of natural history studies is not as well-documented as
the nadir from RESCUE and REVERSE trials, hence limiting the
interpretation of these findings.
Importantly, we included all treated and sham eyes of
unilaterally injected patients in our analyses based on the
assumption that sham eyes were exposed to lenadogene
nolparvovec, presumably by transfer of the viral vector through
the optic chiasm (14). Interestingly, the significant treatment
effect vs. natural history eyes observed when considering all
eyes was maintained in the analyses performed separately
on better eyes and on worse eyes, as seen in Table 3. A
study investigating the effect of unilateral vs. bilateral injection
of lenadogene nolparvovec in MT-ND4 LHON patients is
underway and should provide more information on the
potential additional benefit provided by bilateral treatment with
lenadogene nolparvovec (NCT03293524).
We previously reported that lenadogene nolparvovec
improved visual outcomes up to 96 weeks after treatment in
REVERSE and RESCUE, which corresponds to ∼2.5 years after
vision loss (14, 15). Here we extend these findings by showing the
persistence of visual benefit in the long term, with continuous
improvement in BCVA up to the last available observation
[i.e., 51.5 months (4.3 years) from vision loss]. Moreover, the
long-term trend depicted in the regression analyses suggests that
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visual improvement in treated patients may continue to progress
with time, in line with the improvement noted up to 7 years after
treatment in a small cohort of MT-ND4 LHON patients treated
with another gene therapy product, although the majority of
patients in that study were younger than 15 years in age (16).
Further results of the ongoing CLIN06 study with follow-up
planned for 5 years after treatment (∼6 years after vision loss)
should provide similar information for patients treated with
lenadogene nolparvovec.
To enable a fair comparison in a non-randomized setting and
even more so when using an external comparator, it is essential
that treated and control groups share comparable characteristics.
To ensure the comparability of groups, we carefully selected
natural history patients who would have been eligible for our
gene therapy trials as regards the age of onset and genotype,
two criteria that have been shown to be major determinants
of spontaneous recovery in LHON (10). In this report, both
treated and natural history groups were typical of the general
MT-ND4 LHON population described in the literature, with a
predominance of male patients (around 80%) and a median
age at onset in the 20-30 s (5). It should be noted, however,
that when compared with treated patients, natural history
patients were relatively younger (median age of 23 years vs.
32 years at onset) and were followed for a shorter period
of time (median follow-up of 25 vs. 40 months). However,
because both a younger age at onset and a shorter follow-up
(when visual acuity may not have yet reached its worst level)
are associated with a better visual outcome, this imbalance
between groups was more likely to disadvantage treated eyes,
thus reinforcing the significance of the observed difference
between groups. Indeed when these two confounding variables
were considered in the multivariate analyses, the difference in
visual acuities between treated and natural history eyes was
statistically significant (0.32 LogMAR difference in favor of
treated eyes, p < 0.0001). Furthermore, it should be emphasized
that we also retained natural history patients who may have
been treated with idebenone, further potentially disfavoring the
treated patients who, by study exclusion criteria, were not taking
this medication.
Our study has several limitations. Although we used a
systematic approach in selecting natural history data from the
literature, we excluded studies containing only aggregated patient
visual acuity data, which could have led to a potential bias
in the inclusion of certain patients. Despite this reduction of
the natural history database related to methodological concerns
to enable rigorous indirect comparison analyses, the external
control group ultimately included a substantial number of
patients representative of the MT-ND4 LHON population. The
LOESS method used for describing the evolution of visual
acuity is a non-parametric approach which does not take into
account the intra-patient correlation, leading to a possible
under-estimation of the confidence interval around the fitted
curves. As such, the LOESS analysis should be regarded as
descriptive in nature rather than inferential. However, we also
performed formal statistical tests that took into account the
intra-patient correlation, hence supporting the generalizability of
the treatment effect. Furthermore, the treatment effect observed
for both eyes was similar to that seen for better and worse eyes,
indicating that the impact of inter-eye correlation is minimal on
treatment effect. While the time from vision loss to treatment for
all 152 treated eyes was 12.8 months, we chose to present our
results from month 12. Indeed this does not have any impact
on the interpretations of findings, as nearly all eyes (93%) had
received the treatment by month 12.
Another concern relates to the heterogeneity of the collected
visual acuities in our natural history cohort. Crucially, very few
of the natural history studies specified that the visual acuities
obtained were BCVAs, and there was no standardized assessment
of vision as in rigorously performed clinical trial studies where
LogMAR vision is measured using the ETDRS chart using a
set protocol. Furthermore, most of the natural history studies
were retrospective reviews of their patient cohorts, with most
natural history data being cross-sectional (recorded at individual
points in time) as opposed to longitudinal for treated eyes (several
measurements over time). This difference in the frequency and
number of visual acuity assessments per patient may have had
an impact on the precision of the visual acuity LOESS model
curves for the natural history patients, more so if visual acuity
was not always determined with the optimal refraction. However,
we believe this had a limited impact on the modelized curves
because of the observed stability of the visual acuities over
time across the different natural history studies. Furthermore,
the most important outcome for the patient is the final visual
outcome (last available visual acuity) which was largely reported
many months after visual loss onset in the natural history studies
that we included in our analyses.
Ultimately, a randomized trial vs. a true parallel placebo
group would be the ideal next step to enhance the efficacy
of gene therapy with lenadogene nolparvovec. However, there
are many barriers to this approach, both operationally and
ethically. Among the former include the potentially confounding
concurrent, but non-uniform, use of idebenone and the
challenges of recruitment for this rare disease. Ethical concerns
would include the safety of intravitreal injection of placebo and
the absence or delay of treatment in this neurodegenerative
disease that is rapidly non-reversible.
In summary, we demonstrate that gene therapy with
lenadogene nolparvovec induced a progressive, sustained,
and statistically significant improvement of visual acuity up
to more than 4 years after vision loss in LHON patients
carrying the m.11778G>A mutation when compared to
the spontaneous evolution of a large group of matched
natural history patients used as an external comparator.
Similarly, the same analyses applied to better and worse
eyes and to the REVERSE and RESCUE study populations,
considered independently, show similar results. The sensitivity
analyses controlling for potential confounding factors confirm
the robustness of the indirect comparison results. Finally,
the strong temporal relationship between the start of
improvement and administration of treatment and the size
of the treatment effect observed further support the validity of
our findings.
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